Lymphir
Term · Oncology and biomedicine · MLC-T-ONC-005029
A drug used to treat adults with stage I, stage II, or stage III cutaneous T-cell lymphoma that came back or did not get better after treatment with at least one other systemic therapy. It is also being studied in the treatment of other types of cancer. Lymphir is made by combining interleukin-2 (IL-2) with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and the toxin kills them. Lymphir is a type of immunotoxin and a type of recombinant fusion protein. Also called denileukin diftitox.
| Identifier | MLC-T-ONC-005029 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | denileukin diftitox |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-005029",
"term": "Lymphir",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with stage I, stage II, or stage III cutaneous T-cell lymphoma that came back or did not get better after treatment with at least one other systemic therapy. It is also being studied in the treatment of other types of cancer. Lymphir is made by combining interleukin-2 (IL-2) with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and the toxin kills them. Lymphir is a type of immunotoxin and a type of recombinant fusion protein. Also called denileukin diftitox.",
"synonyms": [
"denileukin diftitox"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/lymphir/"
}
Record 10,464 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.